SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD

NEW YORK, Dec. 1, 2016

The investigation concerns whether Amicus and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. 

[Click here to join a class action]

On November 28, 2016, post-market, Amicus announced that its oral drug Galafold (migalastat) for treating Fabry disease did not meet the U.S. Food and Drug Administration's criteria for an accelerated review, and that the drug's approval will be delayed until at least 2020.  The Company expects to commence clinical trials by next year, and trial data is expected to be available by 2019.  

On this news, Amicus stock fell $1.81, or 21.75%, to close at $6.51 on November 29, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com